Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.77 · Expires 2036-05-20 | Direct | 5,500 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 5,500 · Balance 5,500 F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.77 · Expires 2036-05-20 | Direct | 11,000 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 11,000 · Balance 11,000 F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 20:30 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 11,000 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065755 · tm2615475-1_4seq1.xml · derivative · entry 2 Alex Slanix Paul · CIK 0002092283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2036-05-20 F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:30 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 5,500 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065755 · tm2615475-1_4seq1.xml · derivative · entry 1 Alex Slanix Paul · CIK 0002092283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Shares · 5,500 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:00 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseWarrants · Derivative | 700,741 | Not disclosed Strike: $14.40 | Not disclosed |
DisclosureSEC source: 0001493152-26-005410 · ownership.xml · derivative · entry 2 ABG Management Ltd. · CIK 0001832106 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Alex Slanix Paul · CIK 0002092283 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 700,741 Underlying: Common Shares · 700,741 shares Expires not disclosed F1 · price: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. F6 · derivative.exercise_date: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. F6 · derivative.expiration_date: The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310. F3 · ownership.nature: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. F4 · ownership.nature: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. F5 · ownership.nature: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. F7 · ownership.nature: The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:00 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 700,741 | $12.13 | $8,499,988.33 |
DisclosureSEC source: 0001493152-26-005410 · ownership.xml · nonDerivative · entry 1 ABG Management Ltd. · CIK 0001832106 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Alex Slanix Paul · CIK 0002092283 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 943,090 F1 · price: The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share. F2 · ownership.nature: The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited. F3 · ownership.nature: Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. F4 · ownership.nature: Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. F5 · ownership.nature: Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:34 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001493152-25-019320 · ownership.xml · derivative · entry 1 ABG Management Ltd. · CIK 0001832106 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Alex Slanix Paul · CIK 0002092283 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2035-10-22 F1 · derivative.exercise_date: 25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F2 · ownership.direct: This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.